复星医药 (600196.SH) Latest Company News

Sep 4, 2026, 08:23 UTC
Fosun High Technology, the controlling shareholder of Fosun Pharma, pledged 330 million A-shares to ICBC Shanghai Changning Sub-branch on September 3, 2026, to secure debt repayment.
Source:
- finance.sina.cn
Sep 3, 2026, 16:30 UTC
Fosun Pharma launched a block deal to divest 5% equity in Gland Pharma worth Rs 2,279 crore at a floor price of Rs 2,763 per share.
Source:
- economictimes.indiatimes.com
- businesstoday.in
Sep 3, 2026, 10:01 UTC
China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.
Source:
Sep 3, 2026, 09:44 UTC
Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.
Source:
- finance.sina.cn
Sep 3, 2026, 08:20 UTC
Fosun Pharma's controlled subsidiary received regulatory approval from China's National Medical Products Administration for a new indication of its drug Luwometinib (brand name Fumaining) for adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type I.
Source:
- finance.sina.cn
- aastocks.com
Sep 1, 2026, 09:39 UTC
Fosun Pharma repurchased 264,000 H-shares on the Hong Kong Stock Exchange on September 1, 2026, at prices between HKD 16.07 and HKD 16.28 per share, totaling HKD 4.2784 million, to be held as treasury shares.
Source:
- finance.sina.cn
Aug 31, 2026, 09:52 UTC
Fosun Pharma repurchased 70,500 H shares on the Hong Kong Stock Exchange on August 31, 2026, at prices between HKD 16.01 and 16.05 per share, totaling HKD 1.1302 million, to be held as treasury shares.
Source:
- finance.sina.cn
Aug 27, 2026, 13:58 UTC
Fosun Pharma repurchased 217,000 H-shares on the open market on August 27, 2026, at an average price of HKD 16.53 per share, totaling approximately HKD 3.587 million.
Source:
- aastocks.com
Aug 27, 2026, 11:56 UTC
Fosun Pharma announced that its subsidiary Yaoyu Pharmaceutical's licensed-in drug Weiketuo (GR1803), a BCMA×CD3 bispecific antibody, received conditional approval from China's National Medical Products Administration for treating relapsed or refractory multiple myeloma in adults who have received at least three prior lines of therapy.
Source:
- finance.sina.cn
- aastocks.com
Aug 25, 2026, 09:48 UTC
Fosun Pharma announced its first-half 2026 results: revenue of 20.442 billion yuan, up 4.75% year-on-year; net profit attributable to shareholders of 1.721 billion yuan, up 1.15% year-on-year.
Source:
- finance.sina.cn
- aastocks.com
Aug 21, 2026, 02:35 UTC
Fosun Pharma announced that the first participant in the China Phase I clinical trial of its liver-targeted siRNA drug FXR0906 for hypertriglyceridemia has been dosed.
Source:
- aastocks.com
Aug 18, 2026, 20:30 UTC
Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.
Source:
- jordantimes.com
Aug 16, 2026, 23:48 UTC
Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.
Source:
Aug 13, 2026, 09:43 UTC
Fosun Pharma's controlled subsidiary initiated a Phase II clinical trial in China for FXS7553, a self-developed small-molecule oral DPP-1 inhibitor, to treat chronic obstructive pulmonary disease.
Source:
- aastocks.com
Aug 7, 2026, 11:38 UTC
Fosun Pharma's controlled subsidiary Fosun Pharma (Xuzhou) Co., Ltd. obtained registration approval from the National Medical Products Administration for its levalbuterol hydrochloride nebulized inhalation solution, with the approved indication being the treatment or prevention of related bronchospasm in adults and children over 6 years old.
Source:
- finance.sina.cn
Aug 7, 2026, 11:38 UTC
Fosun Pharma's controlling subsidiary Shanghai Zhaohui Pharmaceutical's dobutamine hydrochloride injection received registration approval from the National Medical Products Administration for treating heart failure.
Source:
- finance.sina.cn
- aastocks.com
Aug 3, 2026, 08:19 UTC
Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical received NMPA registration approval for its compound polyethylene glycol (3350) electrolyte powder, indicated for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.
Source:
- finance.sina.cn
Aug 3, 2026, 08:19 UTC
Fosun Pharma's controlling subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. obtained registration approval from the National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III), indicated to improve glycemic control in adult patients with type 2 diabetes receiving empagliflozin and metformin hydrochloride treatment.
Source:
- finance.sina.cn
Jul 31, 2026, 08:34 UTC
Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.
Source:
Jul 24, 2026, 08:23 UTC
Fosun Pharma's subsidiary Fosun Wanbang received approval from the National Medical Products Administration to conduct a clinical trial for DM1001 to treat Parkinson's disease.
Source:
- finance.sina.cn
Jul 22, 2026, 08:23 UTC
Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 69 million A-shares on July 21, 2026, and disclosed a subsequent pledge plan.
Source:
- finance.sina.cn
Jul 10, 2026, 08:35 UTC
Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.
Source:

600196.SH

Fosun High Technology, the controlling shareholder of Fosun Pharma, pledged 330 million A-shares to ICBC Shanghai Changning Sub-branch on September 3, 2026, to secure debt repayment.

Fosun Pharma launched a block deal to divest 5% equity in Gland Pharma worth Rs 2,279 crore at a floor price of Rs 2,763 per share.

China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.

Fosun Pharma's controlled subsidiary received regulatory approval from China's National Medical Products Administration for a new indication of its drug Luwometinib (brand name Fumaining) for adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type I.

Fosun Pharma repurchased 264,000 H-shares on the Hong Kong Stock Exchange on September 1, 2026, at prices between HKD 16.07 and HKD 16.28 per share, totaling HKD 4.2784 million, to be held as treasury shares.

Fosun Pharma repurchased 70,500 H shares on the Hong Kong Stock Exchange on August 31, 2026, at prices between HKD 16.01 and 16.05 per share, totaling HKD 1.1302 million, to be held as treasury shares.

Fosun Pharma repurchased 217,000 H-shares on the open market on August 27, 2026, at an average price of HKD 16.53 per share, totaling approximately HKD 3.587 million.

Fosun Pharma announced its first-half 2026 results: revenue of 20.442 billion yuan, up 4.75% year-on-year; net profit attributable to shareholders of 1.721 billion yuan, up 1.15% year-on-year.

Fosun Pharma announced that the first participant in the China Phase I clinical trial of its liver-targeted siRNA drug FXR0906 for hypertriglyceridemia has been dosed.

Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.

Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.

Fosun Pharma's controlled subsidiary initiated a Phase II clinical trial in China for FXS7553, a self-developed small-molecule oral DPP-1 inhibitor, to treat chronic obstructive pulmonary disease.

Fosun Pharma's controlling subsidiary Shanghai Zhaohui Pharmaceutical's dobutamine hydrochloride injection received registration approval from the National Medical Products Administration for treating heart failure.

Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical received NMPA registration approval for its compound polyethylene glycol (3350) electrolyte powder, indicated for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.

Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.

Fosun Pharma's subsidiary Fosun Wanbang received approval from the National Medical Products Administration to conduct a clinical trial for DM1001 to treat Parkinson's disease.

Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 69 million A-shares on July 21, 2026, and disclosed a subsequent pledge plan.

Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.